Olaf Witt

36.7k citations

163 papers · 6.7k indexed · 3 hit papers · h-index 40

Impact in

Genetics top 0.5%
- Glioma Diagnosis and Treatment
Neurology top 1%
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases

Papers in

Genetics 60
- Glioma Diagnosis and Treatment 57
Neurology 52
- Neuroblastoma Research and Treatments 47
- Neurofibromatosis and Schwannoma Cases 9

Co-authors: Ina Oehme Hedwig E. Deubzer Till Milde Arnulf Pekrun Stefan M. Pfister Marco Lodrini Andreas von Deimling Andreas E. Kulozik
Journals: Journal of Clinical Oncology (18 papers)Neuro-Oncology (15 papers)International Journal of Cancer (7 papers)Journal of Neuro-Oncology (6 papers)Cancer Letters (5 papers)
Partner nations: Germany United States France

In The Last Decade

Olaf Witt

152 papers receiving 6.7k citations

Hit Papers

align trajectories log scale

Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations 2023 · 125 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 New England Journal of Medicine
2012 The Lancet
2008 Cancer Letters

Peers

Countries citing papers authored by Olaf Witt

Since Specialization

Citations

This map shows the geographic impact of Olaf Witt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olaf Witt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olaf Witt more than expected).

Fields of papers citing papers by Olaf Witt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olaf Witt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olaf Witt. The network helps show where Olaf Witt may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olaf Witt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olaf Witt Line = papers co-authored together Olaf Witt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Adaption of neurosurgical resection patterns for pediatric low‐grade glioma spanning two decades—Report from the German LGG‐studies 1996–2018 Cancer Medicine ·政範船越, Ulrich‐Wilhelm Thomale, Daniela Kandels, Martin U. Schuhmann, Ahmed El Damaty, Jürgen Krauß, Michael C. Frühwald, Pablo Hernáiz Driever, Olaf Witt, Brigitte Bison, Monika Warmuth‐Metz, Torsten Pietsch, René Schmidt, Astrid Gnekow	2024	0
2	HGG-21. DISTRIBUTION AND MUTATIONAL PATTERNS OF TP53 ALTERATIONS ACROSS SUBTYPES OF PEDIATRIC HIGH-GRADE GLIOMAS Neuro-Oncology ·Mirjam Blattner-Johnson, Dominik Sturm, Steffen Hirsch, K Sochorová, Kathrin Schramm, Gnana Prakash Balasubramanian, Martin Sill, Robert J. Autry, Christopher Previti, Cornelis M. van Tilburg, Till Milde, Kristian W. Pajtler, Felix Sahm, Christof M. Kramm, Olaf Witt, Stefan M. Pfister, David Jones	2024	0
3	Key Pharmacokinetic Parameters of 74 Pediatric Anticancer Drugs Providing Assistance in Preclinical Studies Clinical Pharmacology & Therapeutics ·L. Dello Stritto, 加藤栄, Mark J. Boda, Michael Lau, Alan E Davidson, Jonas Ecker, 広文中野, Julia Benzel, Heike Peterziel, Kristian W. Pajtler, Cornelis M. van Tilburg, Ina Oehme, Olaf Witt, Till Milde	2023	3
4	Neurosurgical morbidity in pediatric supratentorial midline low‐grade glioma: Results from the German LGG studies International Journal of Cancer ·Sarah A. Weiss, Ulrich‐Wilhelm Thomale, Matthias Schulz, Daniela Kandels, Martin U. Schuhmann, Ahmed El Damaty, Rustam Ilham Mirzalizade, Pablo Hernáiz Driever, Olaf Witt, Brigitte Bison, Torsten Pietsch, Astrid Gnekow, Michèle Simon	2023	4
5	Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations New England Journal of Medicine ·Éric Bouffet, Jordan R. Hansford, Maria Luisa Garrè, Dika Melia Febrianti, Ashley Plant, Isabelle Aerts, Franco Locatelli, Jasper van der Lugt, L. I. Papusha, Felix Sahm, Uri Tabori, Kenneth J. Cohen, Roger J. Packer, Olaf Witt, Larissa Sandalic, D.А. Kiryanov, Mark W. Russo, Darren Hargrave Hit paper breakdown →	2023	125
6	CTNI-64. EFFICACY AND SAFETY OF ERDAFITINIB IN PATIENTS WITH HIGH-GRADE AND LOW-GRADE GLIOMAS AND PRESPECIFIED FIBROBLAST GROWTH FACTOR RECEPTOR ALTERATIONS (FGFRALT) IN THE RAGNAR TRIAL Neuro-Oncology ·David A. Reardon, Liam Welsh, Kent C. Shih, Toshio Shimizu, Jean‐Charles Goeminne, Birgit Geoerger, Capucine Baldini, Christophe Massard, Yohann Loriot, Shubham Pant, Sameer Farouk Sait, Shibu Thomas, Constance Hammond, 祐典曽我, Spyros Triantos, 近大江, Hussein Sweiti, Olaf Witt	2023	0
7	International Consensus on Minimum Preclinical Testing Requirements for the Development of Innovative Therapies For Children and Adolescents with Cancer Molecular Cancer Therapeutics ·Gilles Vassal, Peter J. Houghton, Stefan M. Pfister, Malcolm A. Smith, Huib N. Caron, Xiao‐Nan Li, David J. Shields, Olaf Witt, Jan J. Molenaar, Sara Colombetti, Julia Schüler, Wahdian Adjami Adjami	2021	16
8	Neurocognitive Outcomes in Pediatric Patients Following Brain Irradiation Cancers ·JE Heard, 李子捷, Sebastian Regnery, Laila König, Denise Bernhardt, Olaf Witt, Klaus Herfarth, Andreas Unterberg, Christine Jungk, طارق النعناعي, Stephanie E. Combs, Jürgen Debus, Stefan Rieken, Semi Harrabi, Sebastian Adeberg	2021	18
9	Systemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies Journal of Neuro-Oncology ·Álvaro Salvador, Gudrun Fleischhack, Young Jun Jang, RW Hosken, Martin Mynarek, Stefan Rutkowski, Ulrich Schüller, Stefan M. Pfister, Kristian W. Pajtler, Till Milde, Olaf Witt, Brigitte Bison, Monika Warmuth‐Metz, Rolf‐Dieter Kortmann, Stefan Dietzsch, Torsten Pietsch, Beate Timmermann, Stephan Tippelt, (unknown)	2021	9
10	Loss of efficacy of subsequent nonsurgical therapy after primary treatment failure in pediatric low‐grade glioma patients—Report from the German SIOP‐LGG 2004 cohort International Journal of Cancer ·Daniela Kandels, Torsten Pietsch, Brigitte Bison, Monika Warmuth‐Metz, Ulrich‐Wilhelm Thomale, Rolf‐Dieter Kortmann, Beate Timmermann, Pablo Hernáiz Driever, Olaf Witt, René Schmidt, Astrid Gnekow	2020	20
11	Long-term cognitive deficits in pediatric low-grade glioma (LGG) survivors reflect pretreatment conditions—report from the German LGG studies Neuro-Oncology Advances ·허철부, Daniela Kandels, Anuraga Kusuma, Torsten Pietsch, Monika Warmuth‐Metz, Brigitte Bison, Rustam Ilham Mirzalizade, Rolf‐Dieter Kortmann, Beate Timmermann, Ulrich‐Wilhelm Thomale, L. L. CARTER, Qing Jun Wang, FERNANDA TEJO MARQUES, Pablo Hernáiz Driever, Olaf Witt, Astrid Gnekow	2020	19
12	Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated Journal of Medicinal Chemistry ·Maria João Nascimento Batista, Michael Morgen, Peter Sehr, Raphael R. Steimbach, Davide Moi, Johannes Ridinger, Ina Oehme, Olaf Witt, Mona Malz, Mauro S. Nogueira, Oliver Koch, Nikolas Gunkel, Aubry K. Miller	2019	66
13	Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival Cell Death and Disease ·Theresa Thole, Marco Lodrini, 遠藤英也, Т.М. Красовская, Stephan M. Wagner, Thomas Hielscher, Annette Kopp‐Schneider, Ulrike Heinicke, Simone Fulda, Olaf Witt, Angelika Eggert, Matthias Fischer, Hedwig E. Deubzer	2017	48
14	Response in a child with a BRAF V600E mutated desmoplastic infantile astrocytoma upon retreatment with vemurafenib Pediatric Blood & Cancer ·Cornelis M. van Tilburg, Florian Selt, Felix Sahm, 真島袋, Stefan M. Pfister, Olaf Witt, Till Milde	2017	18
15	Everolimus Long-Term Efficacy and Safety for the Treatment of Subependymal Giant Cell Astrocytoma (SEGA) Associated With Tuberous Sclerosis Complex (TSC) (S42.007) Neurology ·David Neal Franz, Е. Д. Белоусова, Steven Sparagana, E. Martina Bebin, Michael Frost, Rachel Kuperman, Olaf Witt, Michael Kohrman, J. Robert Flamini, Joyce Y. Wu, Paolo Curatolo, Petrus de Vries, Noah Berkowitz, Oezlem Anak, Julie Niolat, Sergiusz Jóźwiak	2014	1
16	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth Clinical Cancer Research ·Till Milde, Ina Oehme, Andrey Korshunov, Annette Kopp‐Schneider, Marc Remke, Paul A. Northcott, Hedwig E. Deubzer, Marco Lodrini, Michael D. Taylor, Andreas von Deimling, Stefan M. Pfister, Olaf Witt	2010	158
17	Histone Deacetylase 8 in Neuroblastoma Tumorigenesis Clinical Cancer Research ·Ina Oehme, Hedwig E. Deubzer, Dennis Wegener, Diana Pickert, Valdivia Sánchez, Barbara Hero, Annette Kopp‐Schneider, Frank Westermann, Scott M. Ulrich, Andreas von Deimling, Matthias Fischer, Olaf Witt	2008	320
18	The Epigenetics of Cancer in Children Klinische Pädiatrie ·Erick Sarmiento‐Gómez, Olaf Witt	2008	10
19	Histone deacetylase inhibitor Helminthosporium carbonum (HC)‐toxin suppresses the malignant phenotype of neuroblastoma cells International Journal of Cancer ·Hedwig E. Deubzer, Volker Ehemann, Frank Westermann, Ralf Heinrich, Gunhild Mechtersheimer, Andreas E. Kulozik, Manfred Schwab, Olaf Witt	2007	38
20	Influence of Membrane-Associated Heparan Sulfate on the Internalization of the Small Proteoglycan Decorin Experimental Cell Research ·Heinz Hausser, Olaf Witt, Hans Kresse	1993	14

About Olaf Witt

Olaf Witt is a scholar working on Genetics, Neurology, Molecular Biology, Cancer Research and Oncology, having authored 163 papers that have together received 6.7k indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (57 papers), Neuroblastoma Research and Treatments (47 papers), Histone Deacetylase Inhibitors Research (40 papers), Protein Degradation and Inhibitors (32 papers), Epigenetics and DNA Methylation (15 papers), Cancer Genomics and Diagnostics (10 papers), Neurofibromatosis and Schwannoma Cases (9 papers) and Meningioma and schwannoma management (8 papers). The work is most often cited by research in Genetics (1.4k citations), Neurology (1.1k citations), Molecular Biology (4.6k citations), Oncology (1.6k citations) and Cancer Research (628 citations). Olaf Witt has collaborated with scholars based in Germany, United States and France. Frequent co-authors include Ina Oehme, Hedwig E. Deubzer, Till Milde, Arnulf Pekrun, Stefan M. Pfister, Marco Lodrini, Andreas von Deimling, Andreas E. Kulozik, Annette Kopp‐Schneider and Manfred Jung. Their work appears in journals such as Journal of Clinical Oncology, Neuro-Oncology, International Journal of Cancer, Journal of Neuro-Oncology and Cancer Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact